Turning Point Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Turning Point Therapeutics (NASDAQ: TPTX) has announced participation in two upcoming investor conferences. CFO Paolo Tombesi will engage in one-on-one meetings at the 34th Annual Roth Conference on March 15. Following this, President and CEO Athena Countouriotis, M.D., will present a company overview at the Oppenheimer 32nd Annual Healthcare Conference on March 16 from 12:40 to 1:10 p.m. ET, accessible via webcast on the company’s website. TPTX is focused on developing innovative precision oncology therapies targeting genetic drivers of cancer.

SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced its participation in the following investor conferences:

March 15, 34^th Annual Roth Conference, CFO Paolo Tombesi is scheduled to participate in one-on-one meetings.

March 16, Oppenheimer 32^nd Annual Healthcare Conference, President and CEO Athena Countouriotis, M.D., is scheduled to present a company overview from 12:40 to 1:10 p.m. ET.

Dr. Countouriotis’ session will be accessible via webcast through the Investors page of www.tptherapeutics.com.

About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes elzovantinib, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

Contact:
Adam Levy
ir@tptherapeutics.com
858-867-6366

FAQ

What events is Turning Point Therapeutics participating in March 2022?

Turning Point Therapeutics is participating in the 34th Annual Roth Conference on March 15 and the Oppenheimer 32nd Annual Healthcare Conference on March 16.

Who will present at the Oppenheimer Conference for TPTX?

President and CEO Athena Countouriotis, M.D., will present at the Oppenheimer Conference on March 16.

What is the date and time of TPTX's presentation at the Oppenheimer Conference?

Turning Point Therapeutics will present at the Oppenheimer Conference on March 16 from 12:40 to 1:10 p.m. ET.

How can I access the webcast of TPTX's presentation?

The webcast of Turning Point Therapeutics' presentation can be accessed through the Investors page on their official website.

What is the focus of Turning Point Therapeutics' drug candidates?

Turning Point Therapeutics focuses on developing therapies that target genetic drivers of cancer, including drugs for non-small cell lung cancer and advanced solid tumors.